COVIVIO (COV.PA) Fundamental Analysis & Valuation

EPA:COV • FR0000064578

Current stock price

53.75 EUR
+0.35 (+0.66%)
Last:

This COV.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. COV.PA Profitability Analysis

1.1 Basic Checks

  • COV had positive earnings in the past year.
  • In the past year COV had a positive cash flow from operations.
  • Of the past 5 years COV 4 years were profitable.
  • COV had a positive operating cash flow in 4 of the past 5 years.
COV.PA Yearly Net Income VS EBIT VS OCF VS FCFCOV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B -1B

1.2 Ratios

  • COV's Return On Assets of 1.63% is on the low side compared to the rest of the industry. COV is outperformed by 61.90% of its industry peers.
  • The Return On Equity of COV (5.08%) is comparable to the rest of the industry.
  • COV has a Return On Invested Capital (3.21%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA 1.63%
ROE 5.08%
ROIC 3.21%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
COV.PA Yearly ROA, ROE, ROICCOV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10

1.3 Margins

  • Looking at the Profit Margin, with a value of 30.46%, COV is in line with its industry, outperforming 45.24% of the companies in the same industry.
  • COV's Profit Margin has improved in the last couple of years.
  • COV has a worse Operating Margin (57.81%) than 64.29% of its industry peers.
  • In the last couple of years the Operating Margin of COV has grown nicely.
  • Looking at the Gross Margin, with a value of 74.42%, COV is in line with its industry, outperforming 57.14% of the companies in the same industry.
  • In the last couple of years the Gross Margin of COV has remained more or less at the same level.
Industry RankSector Rank
OM 57.81%
PM (TTM) 30.46%
GM 74.42%
OM growth 3Y11.41%
OM growth 5Y7.53%
PM growth 3Y16.3%
PM growth 5Y17.87%
GM growth 3Y2.18%
GM growth 5Y0.71%
COV.PA Yearly Profit, Operating, Gross MarginsCOV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. COV.PA Health Analysis

2.1 Basic Checks

  • COV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • COV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
COV.PA Yearly Shares OutstandingCOV.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
COV.PA Yearly Total Debt VS Total AssetsCOV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

  • COV has an Altman-Z score of 0.53. This is a bad value and indicates that COV is not financially healthy and even has some risk of bankruptcy.
  • COV has a Altman-Z score of 0.53. This is in the lower half of the industry: COV underperforms 71.43% of its industry peers.
  • The Debt to FCF ratio of COV is 28.49, which is on the high side as it means it would take COV, 28.49 years of fcf income to pay off all of its debts.
  • COV has a Debt to FCF ratio of 28.49. This is in the lower half of the industry: COV underperforms 61.90% of its industry peers.
  • A Debt/Equity ratio of 1.07 is on the high side and indicates that COV has dependencies on debt financing.
  • The Debt to Equity ratio of COV (1.07) is worse than 78.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF 28.49
Altman-Z 0.53
ROIC/WACC0.56
WACC5.74%
COV.PA Yearly LT Debt VS Equity VS FCFCOV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B 10B

2.3 Liquidity

  • A Current Ratio of 0.76 indicates that COV may have some problems paying its short term obligations.
  • COV has a Current ratio (0.76) which is comparable to the rest of the industry.
  • A Quick Ratio of 0.69 indicates that COV may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.69, COV perfoms like the industry average, outperforming 59.52% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.69
COV.PA Yearly Current Assets VS Current LiabilitesCOV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. COV.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 6.26% over the past year.
  • The Earnings Per Share has been growing slightly by 2.44% on average over the past years.
  • The Revenue for COV has decreased by -11.71% in the past year. This is quite bad
  • COV shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.03% yearly.
EPS 1Y (TTM)6.26%
EPS 3Y1.22%
EPS 5Y2.44%
EPS Q2Q%6.28%
Revenue 1Y (TTM)-11.71%
Revenue growth 3Y-8.88%
Revenue growth 5Y-2.03%
Sales Q2Q%40.47%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.42% on average over the next years.
  • The Revenue is expected to grow by 9.64% on average over the next years. This is quite good.
EPS Next Y2.32%
EPS Next 2Y3.02%
EPS Next 3Y3.42%
EPS Next 5YN/A
Revenue Next Year4.53%
Revenue Next 2Y5.13%
Revenue Next 3Y9.64%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
COV.PA Yearly Revenue VS EstimatesCOV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M 1B
COV.PA Yearly EPS VS EstimatesCOV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

5

4. COV.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • COV is valuated reasonably with a Price/Earnings ratio of 11.32.
  • 66.67% of the companies in the same industry are more expensive than COV, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 26.17. COV is valued rather cheaply when compared to this.
  • The Price/Forward Earnings ratio is 11.06, which indicates a very decent valuation of COV.
  • COV's Price/Forward Earnings ratio is in line with the industry average.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.05, COV is valued rather cheaply.
Industry RankSector Rank
PE 11.32
Fwd PE 11.06
COV.PA Price Earnings VS Forward Price EarningsCOV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, COV is valued a bit cheaper than 64.29% of the companies in the same industry.
  • COV's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 15.28
EV/EBITDA 16.76
COV.PA Per share dataCOV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates COV does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)4.88
PEG (5Y)4.63
EPS Next 2Y3.02%
EPS Next 3Y3.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. COV.PA Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 7.46%, COV is a good candidate for dividend investing.
  • COV's Dividend Yield is a higher than the industry average which is at 5.32.
  • Compared to an average S&P500 Dividend Yield of 1.89, COV pays a better dividend.
Industry RankSector Rank
Dividend Yield 7.46%

5.2 History

  • The dividend of COV decreases each year by -1.54%.
Dividend Growth(5Y)-1.54%
Div Incr Years3
Div Non Decr Years3
COV.PA Yearly Dividends per shareCOV.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4

5.3 Sustainability

  • 92.76% of the earnings are spent on dividend by COV. This is not a sustainable payout ratio.
DP92.76%
EPS Next 2Y3.02%
EPS Next 3Y3.42%
COV.PA Yearly Income VS Free CF VS DividendCOV.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B
COV.PA Dividend Payout.COV.PA Dividend Payout, showing the Payout Ratio.COV.PA Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

COV.PA Fundamentals: All Metrics, Ratios and Statistics

COVIVIO

EPA:COV (4/2/2026, 7:00:00 PM)

53.75

+0.35 (+0.66%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Earnings (Last)02-18
Earnings (Next)07-20
Inst Owners41.1%
Inst Owner ChangeN/A
Ins Owners0.27%
Ins Owner ChangeN/A
Market Cap6.00B
Revenue(TTM)1.15B
Net Income(TTM)417.86M
Analysts74.67
Price Target64.78 (20.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 7.46%
Yearly Dividend0.72
Dividend Growth(5Y)-1.54%
DP92.76%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.78%
PT rev (3m)0.1%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)1.65%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.39%
Revenue NY rev (3m)-0.18%
Valuation
Industry RankSector Rank
PE 11.32
Fwd PE 11.06
P/S 4.37
P/FCF 15.28
P/OCF 5.98
P/B 0.73
P/tB 0.76
EV/EBITDA 16.76
EPS(TTM)4.75
EY8.84%
EPS(NY)4.86
Fwd EY9.04%
FCF(TTM)3.52
FCFY6.54%
OCF(TTM)8.99
OCFY16.72%
SpS12.29
BVpS73.66
TBVpS70.57
PEG (NY)4.88
PEG (5Y)4.63
Graham Number88.73
Profitability
Industry RankSector Rank
ROA 1.63%
ROE 5.08%
ROCE 3.59%
ROIC 3.21%
ROICexc 3.42%
ROICexgc 3.48%
OM 57.81%
PM (TTM) 30.46%
GM 74.42%
FCFM 28.62%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y11.41%
OM growth 5Y7.53%
PM growth 3Y16.3%
PM growth 5Y17.87%
GM growth 3Y2.18%
GM growth 5Y0.71%
F-Score7
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF 28.49
Debt/EBITDA 9.39
Cap/Depr 415.79%
Cap/Sales 44.53%
Interest Coverage 250
Cash Conversion 106.76%
Profit Quality 93.95%
Current Ratio 0.76
Quick Ratio 0.69
Altman-Z 0.53
F-Score7
WACC5.74%
ROIC/WACC0.56
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.26%
EPS 3Y1.22%
EPS 5Y2.44%
EPS Q2Q%6.28%
EPS Next Y2.32%
EPS Next 2Y3.02%
EPS Next 3Y3.42%
EPS Next 5YN/A
Revenue 1Y (TTM)-11.71%
Revenue growth 3Y-8.88%
Revenue growth 5Y-2.03%
Sales Q2Q%40.47%
Revenue Next Year4.53%
Revenue Next 2Y5.13%
Revenue Next 3Y9.64%
Revenue Next 5YN/A
EBIT growth 1Y-0.73%
EBIT growth 3Y1.52%
EBIT growth 5Y5.34%
EBIT Next Year7.24%
EBIT Next 3Y6.63%
EBIT Next 5YN/A
FCF growth 1Y-30.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.27%
OCF growth 3YN/A
OCF growth 5YN/A

COVIVIO / COV.PA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for COVIVIO?

ChartMill assigns a fundamental rating of 3 / 10 to COV.PA.


What is the valuation status for COV stock?

ChartMill assigns a valuation rating of 5 / 10 to COVIVIO (COV.PA). This can be considered as Fairly Valued.


What is the profitability of COV stock?

COVIVIO (COV.PA) has a profitability rating of 4 / 10.


Can you provide the financial health for COV stock?

The financial health rating of COVIVIO (COV.PA) is 1 / 10.


What is the earnings growth outlook for COVIVIO?

The Earnings per Share (EPS) of COVIVIO (COV.PA) is expected to grow by 2.32% in the next year.